Winston Pharmaceuticals (Winston Pharmaceuticals) EBIT per Share : $-0.04 (TTM As of Mar. 2010)

View and export this data going back to 2006. Start your Free Trial

What is Winston Pharmaceuticals EBIT per Share?

Winston Pharmaceuticals's EBIT per Share for the three months ended in Mar. 2010 was $-0.01. Its EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2010 was $-0.04.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for Winston Pharmaceuticals's EBIT per Share or its related term are showing as below:

WPHM's 3-Year EBIT Growth Rate is not ranked ^*
in the Drug Manufacturers industry.
Industry Median: 7.4
* Ranked among companies with meaningful 3-Year EBIT Growth Rate only.

Winston Pharmaceuticals's EBIT for the three months ended in Mar. 2010 was $-0.46 Mil.

Winston Pharmaceuticals EBIT per Share Historical Data

The historical data trend for Winston Pharmaceuticals's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Winston Pharmaceuticals EBIT per Share Chart

Winston Pharmaceuticals Annual Data

Trend

Sep05

Sep06

Sep07

Dec08

Dec09

EBIT per Share

-0.35

-0.70

-0.13

-0.10

-0.05

Winston Pharmaceuticals Quarterly Data
	Sep05	Dec05	Mar06	Jun06	Sep06	Dec06	Mar07	Jun07	Sep07	Dec07	Mar08	Jun08	Sep08	Dec08	Mar09	Jun09	Sep09	Dec09	Mar10
EBIT per Share	Get a 7-Day Free Trial														-0.01	-0.01	-0.01	-0.01	-0.01

Winston Pharmaceuticals EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

Winston Pharmaceuticals's EBIT per Share for the fiscal year that ended in Dec. 2009 is calculated as

	EBIT per Share		(A: Dec. 2009 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-2.741	/	61.258
=	-0.04

Winston Pharmaceuticals's EBIT per Share for the quarter that ended in Mar. 2010 is calculated as

	EBIT per Share		(Q: Mar. 2010 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-0.462	/	77.409
=	-0.01

EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2010 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.04

Winston Pharmaceuticals (GREY:WPHM) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

Winston Pharmaceuticals EBIT per Share Related Terms

Thank you for viewing the detailed overview of Winston Pharmaceuticals's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Winston Pharmaceuticals (Winston Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Winston Pharmaceuticals Inc (GREY:WPHM) » Definitions » EBIT per Share

Comparable Companies

Traded in Other Exchanges

N/A

Address

100 North Fairway Drive, Suite 134, Vernon Hills, IL, USA, 60061

Website

http://www.winstonlabs.com

Winston Pharmaceuticals Inc is a pharmaceutical company, which is engaged in the discovery and development of products for pain management. The company focuses on major pain indications such as episodic cluster headache, chronic migraine headache, neuropathic pain syndromes, osteo- and rheumatoid arthritis, and pain and inflammation in inflammatory bowel disease.

Executives

Frost Phillip Md Et Al	10 percent owner	4400 BISCAYNE BLVD, MIAMI FL 33137-3227
Frost Gamma Investments Trust	10 percent owner	4400 BISCAYNE BLVD, MIAMI FL 33137
Subbarao V Uppaluri	director	4400 BISCAYNE BOULEVARD, SUITE 1500, MIAMI FL 33137
Curtis Lockshin	director	4400 BISCAYNE BOULEVARD, SUITE 950, MIAMI FL 33137
Glenn L Halpryn	director	4400 BISCAYNE BOULEVARD, SUITE 950, MIAMI FL 33137
Steven Jerry Glauser	10 percent owner	1428 BRICKELL AVENUE, SUITE 105, MIAMI FL 33131
Noah M Silver	director, officer: Vice President	4400 BISCAYNE BOULEVARD, SUITE 950, MIAMI FL 33137
Alan Jay Weisberg	director, officer: Chief Financial Officer	2500 NORTH MILITARY TRAIL, SUITE 206, BOCA RATON FL 33431
Stephen Bittel	10 percent owner	4400 BISCAYNE BOULEVARD SUITE 950 MIAMI FL 33137

Winston Pharmaceuticals (Winston Pharmaceuticals) Headlines

No Headlines